Summary

Eligibility
for people ages 50-89 (full criteria)
Location
at Irvine, California and other locations
Dates
study started
completion around

Description

Summary

The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.

Official Title

A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Details

Keywords

Alzheimer Disease, Mild Cognitive Impairment, Mild Alzheimer's Disease, Early Alzheimer's disease, Thiamine, Benphothiamine, Low Dose Benfotiamine, High Dose Benfotiamine

Eligibility

Locations

  • University of California, Irvine accepting new patients
    Irvine California 92697 United States
  • Syrentis Clinical Research accepting new patients
    Santa Ana California 92705 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Alzheimer's Disease Cooperative Study (ADCS)
ID
NCT06223360
Phase
Phase 2 Alzheimer's Disease Research Study
Study Type
Interventional
Participants
Expecting 406 study participants
Last Updated